![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF101 |
Gene summary for ZNF101 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF101 | Gene ID | 94039 |
Gene name | zinc finger protein 101 | |
Gene Alias | HZF12 | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8IZC7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
94039 | ZNF101 | HCC1_Meng | Human | Liver | HCC | 1.41e-05 | -1.56e-02 | 0.0246 |
94039 | ZNF101 | HCC1 | Human | Liver | HCC | 7.91e-15 | 1.98e+00 | 0.5336 |
94039 | ZNF101 | HCC2 | Human | Liver | HCC | 1.85e-22 | 2.61e+00 | 0.5341 |
94039 | ZNF101 | HCC5 | Human | Liver | HCC | 1.65e-19 | 2.04e+00 | 0.4932 |
94039 | ZNF101 | S015 | Human | Liver | HCC | 2.10e-04 | 2.28e-01 | 0.2375 |
94039 | ZNF101 | S016 | Human | Liver | HCC | 2.77e-03 | 1.10e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF101 | SNV | Missense_Mutation | rs375316779 | c.386N>A | p.Arg129Gln | p.R129Q | Q8IZC7 | protein_coding | tolerated(0.18) | benign(0.093) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF101 | SNV | Missense_Mutation | novel | c.78N>T | p.Lys26Asn | p.K26N | Q8IZC7 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ZNF101 | SNV | Missense_Mutation | novel | c.163N>A | p.Leu55Met | p.L55M | Q8IZC7 | protein_coding | deleterious(0.01) | benign(0.333) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ZNF101 | SNV | Missense_Mutation | novel | c.816N>C | p.Glu272Asp | p.E272D | Q8IZC7 | protein_coding | deleterious(0) | benign(0.431) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ZNF101 | SNV | Missense_Mutation | novel | c.1064N>T | p.Arg355Ile | p.R355I | Q8IZC7 | protein_coding | tolerated(0.45) | benign(0.02) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ZNF101 | SNV | Missense_Mutation | c.1004N>G | p.Glu335Gly | p.E335G | Q8IZC7 | protein_coding | deleterious(0.01) | benign(0.077) | TCGA-LG-A6GG-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF101 | SNV | Missense_Mutation | rs200536821 | c.397G>T | p.Gly133Cys | p.G133C | Q8IZC7 | protein_coding | tolerated(0.14) | possibly_damaging(0.839) | TCGA-49-6761-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZNF101 | SNV | Missense_Mutation | novel | c.122N>T | p.Ala41Val | p.A41V | Q8IZC7 | protein_coding | tolerated(0.06) | probably_damaging(0.954) | TCGA-22-4596-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF101 | SNV | Missense_Mutation | c.497N>G | p.Lys166Arg | p.K166R | Q8IZC7 | protein_coding | deleterious(0.05) | benign(0.012) | TCGA-60-2710-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | pemetrexed | SD | |
ZNF101 | SNV | Missense_Mutation | novel | c.215G>T | p.Gly72Val | p.G72V | Q8IZC7 | protein_coding | deleterious(0.01) | benign(0.065) | TCGA-63-A5MM-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |